Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIVIS 03 DNA/MVA HIV-1 vaccine trial in Tanzania
ISRCTN90053831Phase 2Completed
- Sponsor
- Swedish Institute for Infectious Disease Control
- Start
- Feb 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of plasmid DNA HIV-1 vaccine and MVA-CMDR in Human immunodeficiency virus infection type 1 (4 arms), sponsored by Swedish Institute for Infectious Disease Control. Primary endpoints: Safety by routine biochemistry and haematology, Safety by electrocardiogram and 3 more. Started Feb 2007; status: completed.
02
Drugs
plasmid DNA HIV-1 vaccineMVA-CMDR
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ISRCTN90053831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90053831.